Evidence map›Paper›PMID 39201718›Full record

ReviewInternational journal of molecular sciences2024

Leveraging PARP-1/2 to Target Distant Metastasis.

Mallory I Frederick, Djihane Abdesselam, Anna Clouvel, Laurent Croteau, Saima Hassan

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mallory I FrederickFaculty of Medicine, Université de Montréal, Montreal, QC H3C 3T5, Canada.
Djihane AbdesselamFaculty of Medicine, Université de Montréal, Montreal, QC H3C 3T5, Canada.
Anna ClouvelCentre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), l'Institut de Cancer de Montreal, Montreal, QC H2X 0A9, Canada.ORCID 0009-0008-7380-5666
Laurent CroteauFaculty of Medicine, Université de Montréal, Montreal, QC H3C 3T5, Canada.
Saima HassanFaculty of Medicine, Université de Montréal, Montreal, QC H3C 3T5, Canada.ORCID 0000-0003-0232-2807

Funding

Centre de Recherche de Centre hospitalier de l'Université de Montréal NAInstitut de Cancer de Montréal NAScotiabank Chair in the diagnosis and treatment of breast cancer NA
6 · The paper itself

Abstract

Poly (ADP-Ribose) Polymerase (PARP) inhibitors have changed the outcomes and therapeutic strategy for several cancer types. As a targeted therapeutic mainly for patients with

Indexed as

Neoplasm MetastasisNeoplasmsPoly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) Polymerase InhibitorsPoly(ADP-ribose) PolymerasesAnimalsDNA RepairEpithelial-Mesenchymal TransitionHumansPARP1 protein, humanPARP2 protein, humanPoly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) Polymerase InhibitorsPoly(ADP-ribose) PolymerasescancermetastasisPARP-1PARP-2PARP inhibitorstumor microenvironment

Identifiers

PMID39201718
PMCPMC11354653

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.